rs17300539 — ADIPOQ -11391G>A

Promoter variant affecting adiponectin secretion and metabolic syndrome risk

See your personal result for ADIPOQ

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

The Adiponectin Paradox — When More Isn't Always Better

Adiponectin is your body's master metabolic regulator11 regulator
a hormone secreted by fat tissue that enhances insulin sensitivity, reduces inflammation, and protects against metabolic disease, and the ADIPOQ gene controls how much of it you produce. The rs17300539 variant sits in the gene's promoter region — the control switch that determines transcription activity22 transcription activity
how actively the gene is read and translated into protein. What makes this variant fascinating is its paradoxical effects: the A allele cranks up adiponectin production, yet doesn't always deliver the metabolic protection you'd expect.

Normally, higher adiponectin is protective — it improves insulin sensitivity, lowers inflammation, reduces cardiovascular risk, and guards against type 2 diabetes. People with obesity and metabolic syndrome typically have low adiponectin levels33 low adiponectin levels
adiponectin secretion is impaired in obesity, creating a vicious cycle of worsening insulin resistance, which contributes to their disease. Yet your genotype at rs17300539 introduces a twist: some people produce more adiponectin but still face elevated metabolic risk.

The Mechanism

The rs17300539 SNP is a G-to-A substitution at position -11391 in the ADIPOQ promoter region. In vitro studies44 In vitro studies
laboratory experiments using cell cultures demonstrate that the A allele significantly increases transcriptional activity compared to the G allele, driving higher adiponectin production. The variant likely alters transcription factor binding55 transcription factor binding
proteins that attach to DNA and regulate gene expression at this promoter site, though the exact factors involved haven't been fully mapped.

Adiponectin circulates in your blood in three forms: low molecular weight (LMW) trimers, medium molecular weight (MMW) hexamers, and high molecular weight (HMW) multimers66 low molecular weight (LMW) trimers, medium molecular weight (MMW) hexamers, and high molecular weight (HMW) multimers. The HMW form is the most biologically active — it's the one that enhances insulin sensitivity77 enhances insulin sensitivity
stimulates AMPK activation in muscle and liver, increasing glucose uptake and fatty acid oxidation and delivers cardiovascular protection. Some evidence suggests that rs17300539 may influence the ratio of HMW to total adiponectin88 ratio of HMW to total adiponectin, which could explain why total adiponectin levels don't always predict metabolic outcomes in carriers.

The Evidence

The Framingham Offspring Study99 Framingham Offspring Study
a landmark cardiovascular epidemiology study following multiple generations genotyped 2,543 participants and found that the A allele at rs17300539 showed the strongest association with higher adiponectin levels (P = 2.6 × 10⁻⁸). Each A allele added roughly 1.6 μg/mL to circulating adiponectin. This finding has been replicated across multiple populations — European, Asian, and Latino cohorts all show the same pattern.

But here's the paradox: a 2009 study in obese children1010 a 2009 study in obese children
1,210 Greek children aged 9-13, both obese and non-obese found that A-allele carriers (GA+AA) had higher adiponectin levels but also higher BMI (B = 0.97, P = 0.015) and a 35% increased odds of obesity (OR = 1.35, 95% CI 1.06-1.85). Before adjusting for obesity status, they showed higher fasting insulin and higher HOMA-IR (a measure of insulin resistance). The researchers concluded that "the rs17300539-A variant, though consistently associated with higher adiponectin levels, does not exert any appreciable protective metabolic effect in children."

In adults, the story differs by baseline metabolic health. A 2023 study in 329 obese Caucasian adults1111 A 2023 study in 329 obese Caucasian adults
Spanish cohort with mean BMI 47.8 kg/m² found that GG homozygotes had significantly higher rates of metabolic syndrome (86% vs. 73.9%, P < 0.05), hypertriglyceridemia, hyperglycemia, and insulin resistance (HOMA-IR 7.49 vs. 4.62) compared to A-allele carriers. GG carriers also had lower adiponectin levels (4.27 vs. 6.36 μg/mL). Logistic regression confirmed that the GG genotype independently increased metabolic syndrome risk (OR = 2.52, 95% CI 1.04-6.10) even after adjusting for age, sex, weight, and dietary intake.

The variant also shows strong association with polycystic ovary syndrome (PCOS)1212 strong association with polycystic ovary syndrome (PCOS) in Chinese populations — a family-based transmission disequilibrium test in 197 PCOS families confirmed overtransmission of the risk allele. PCOS is fundamentally a condition of insulin resistance and hyperandrogenism, often accompanied by low adiponectin.

A meta-analysis of 35 studies1313 A meta-analysis of 35 studies
nearly 29,000 participants across multiple ethnicities linked rs17300539 to coronary artery disease (CAD) risk, though effect sizes varied by population and the direction wasn't always consistent — likely reflecting the complex interplay between adiponectin levels, HMW ratio, and other metabolic factors.

Practical Actions

The clearest clinical implication emerges from the bariatric surgery literature1414 bariatric surgery literature: A-allele carriers show better lipid profile improvements after surgery. In 60 extremely obese individuals followed for 32 months post-surgery, those with the A-C haplotype (combining rs17300539-A with rs266729-C) had greater reductions in LDL cholesterol. This suggests that in the context of major metabolic intervention — whether bariatric surgery or intensive lifestyle modification — the A allele's adiponectin-boosting effect finally translates into benefit.

The gene-diet interaction studies1515 gene-diet interaction studies are particularly relevant. In the RISCK study, rs17300539 genotype interacted significantly with dietary fat composition to determine adiponectin levels. Another study in the GOLDN cohort1616 Another study in the GOLDN cohort found that the association between the -11391A allele and lower BMI was modified by monounsaturated fatty acid (MUFA) intake — A-allele carriers who consumed higher MUFA had the lowest BMI and obesity risk.

Fish oil supplementation may be particularly relevant: omega-3 fatty acids activate PPARγ1717 omega-3 fatty acids activate PPARγ, which upregulates adiponectin expression, and one study found that ADIPOQ genotype modified the response to fish oil supplementation in older individuals.

Interactions

The ADIPOQ gene sits at the intersection of several metabolic pathways. Adiponectin signals through two receptors — AdipoR11818 AdipoR1
predominantly expressed in skeletal muscle, activates AMPK pathways and AdipoR21919 AdipoR2
predominantly in liver, activates PPARα signaling. The downstream effects include increased fatty acid oxidation, reduced hepatic glucose production, and improved insulin sensitivity.

Three other common ADIPOQ SNPs show linkage disequilibrium with rs17300539: rs266729 (-11377C>G, also in the promoter, r² = 0.80 with rs17300539), rs2241766 (+45T>G in exon 2, also called Gly15Gly), and rs1501299 (+276G>T in intron 2). These variants may compound or modify effects, particularly regarding the HMW adiponectin ratio. Haplotype analysis sometimes reveals stronger associations than single SNPs alone.

There's emerging evidence for interaction with TCF7L2 variants2020 TCF7L2 variants, the strongest type 2 diabetes risk gene. TCF7L2 regulates adipocyte development and function, and deletion of TCF7L2 in adipocytes impairs glucose tolerance and alters lipid metabolism. The combination of ADIPOQ and TCF7L2 risk variants may identify individuals who benefit most from dietary fat modification.

Finally, the obesity paradox deserves emphasis: if you're lean and metabolically healthy, higher adiponectin from the A allele is likely beneficial. But if you're already obese or insulin-resistant, the A allele may signal a compensatory response — your body is pumping out more adiponectin to counteract metabolic dysfunction, but it's not enough to overcome the underlying problem. In that scenario, the GG genotype's association with lower adiponectin may simply reflect better baseline metabolic health.

Nutrient Interactions

omega-3 fatty acids altered_metabolism
monounsaturated fats altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant.

GG Lower Adiponectin Normal

Standard adiponectin production with higher metabolic syndrome risk if obese

You have the GG genotype at rs17300539, which is associated with standard (lower) adiponectin production. About 86% of people of European descent share this genotype. In the context of obesity, GG carriers face higher risk of metabolic syndrome, insulin resistance, and dyslipidemia compared to A-allele carriers. However, this doesn't mean your adiponectin levels are inherently problematic — it means you lack the compensatory boost that A-allele carriers get. If you maintain a healthy weight and active lifestyle, your metabolic profile may actually be better than A-carriers at the same weight.

AG Moderately Elevated Adiponectin Intermediate

Moderately increased adiponectin with complex metabolic effects

The paradoxical effects of this variant likely reflect the complexity of adiponectin biology. Total adiponectin levels don't tell the whole story — the ratio of high molecular weight (HMW) to total adiponectin matters more for metabolic outcomes. Your genotype may influence this ratio, though research is still emerging. Additionally, your response to dietary fats appears to be genotype-dependent: AG carriers who consume higher monounsaturated fats show better weight outcomes than GG carriers with the same diet.

AA Elevated Adiponectin High

Significantly elevated adiponectin production with paradoxical metabolic effects

The childhood obesity paradox is most pronounced in AA homozygotes — studies show higher BMI and obesity risk despite elevated adiponectin. This suggests that in early life or in the setting of caloric excess, the A allele may actually promote fat storage. The mechanism isn't fully understood but may involve altered HMW adiponectin ratios or differential signaling through AdipoR1 vs. AdipoR2 receptors.

However, multiple studies in obese adults show AA carriers have better metabolic profiles than GG carriers at the same BMI — lower triglycerides, better insulin sensitivity, reduced metabolic syndrome risk. The bariatric surgery literature is particularly encouraging: AA carriers (especially with the A-C haplotype combining rs17300539-A and rs266729-C) show superior lipid profile improvements post-surgery.

Gene-diet interaction studies reveal that your genotype modifies the metabolic response to dietary fat. AA carriers who consume higher monounsaturated fats have significantly lower BMI and obesity risk than GG carriers eating the same diet.